The IDN Pharmacy supply chain plays a vital role in patient outcomes. IDN pharmacy executives continue to look for innovative methods of improving quality while keeping costs low. Nonetheless, concerns facing the pharmacy segment of healthcare are highly nuanced and complex. This track will prepare you for 2026 and beyond as you examine critical topics from 340B compliance to ensuring revenue integrity facing supply chain leaders and pharmacy executives alike. 

Pharmacy Revenue Track is from 1:00 PM to 5:00 PM on Monday, August 25. For more information contact Trey Beuttel or call 859.523.5701

1:00 PM - 2:00 PM

The gap between pharmacy and finance has never been more critical—or more complex. As drug costs rise and reimbursement pressures increase, the alignment between pharmacy operations and financial strategy is essential to both fiscal sustainability and patient access. Yet, many organizations still struggle with communication obstacles, misaligned priorities, and unclear ownership over cost and margin management.

 

Join pharmacy leaders and explore the often-blurred lines between pharmacy and finance, highlighting how collaboration can be strengthened to drive shared goals and bridge the gap between these two critical departments. 

 

Learning Objectives:
1. Differentiate roles, priorities, and financial metrics valued by pharmacy versus finance within an IDN.
2. Identify common barriers to collaboration between pharmacy and finance teams, and strategies to overcome them.
3. Analyze applicable examples of how improved alignment has impacted decision-making, budgeting, and drug cost containment.
4. Construct a cross-departmental communication framework to support mutual understanding.

2:30 PM - 3:30 PM

As legal scrutiny and regulatory uncertainty continue to surround the topic of 340B, pharmacy leaders must stay up to date on the latest developments to protect program integrity and ensure compliance. The policy landscape is shifting all the time,  with changes to contract pharmacy arrangements, manufacturer restrictions, and audit practices reshaping how 340B is implemented across IDNs.

 

Join Mark Ogunsusi and explore a timely update on the evolution and advancement of 340B, its impact on your organization, and strategies for adapting to a program that continues to face intense external pressure.

 

Learning Objectives:
1. Outline recent legal and regulatory developments impacting the 340B program and their implications for covered entities.
2. Identify high-risk areas for non-compliance within 340B operations and contract pharmacy relationships.
3. Evaluate the impact of manufacturer restrictions and federal oversight on 340B savings and access.
4. Formulate strategies to maintain program integrity and optimize participation amid a shifting legal environment.

4:00 PM - 5:00 PM

Navigating the complex web of payors, prior authorization processes, and pharmacy benefit managers (PBMs) has become a daily operational challenge for pharmacy leaders across IDNs. These three forces significantly impact patient access, drug reimbursement, and the overall efficiency of pharmacy services – often in ways that can be misaligned with clinical and financial goals.

 

Join pharmacy experts and break down how each “P” influences pharmacy operations and revenue cycles, providing real-world insights into policy trends, payor negotiations, and authorization barriers. 

 

Learning Objectives:
1. Describe the distinct roles that payors, PBMs, and prior authorization processes play in influencing pharmacy reimbursement and patient access.
2. Analyze how policy shifts and payor behaviors are shaping prior authorization requirements and timelines.
3. Differentiate the strategies IDNs can use to manage payor and PBM relationships more effectively.
4. Construct an action plan to streamline prior authorization workflows and reduce operational inefficiencies.

For more information on the 2025 Fall Summit, please contact Trey Beuttel.

Trey Beuttel
Director, Provider Relationships and Education
859.523.5701